Additional Information
Content
The export of innovation to China
The latest company to establish a large research facility in China comes from the drugs industry, one of the sectors which has been the least aggressive in off-shoring to low-cost labour destinations.
Now, AstraZeneca has announced its intentions to invest $100m in a research facility in China, focusing on the relationship between cancer and genetics in Chinese patients. The centre, which is likely to be built in Shanghai in 2009, will also be used to create links with academic research centres in China.
Other pharma companies which have already set up research facilities in China include Novo Nordisk, Eli Lilly and Pfizer. The trend in China has been matched by similar developments in India, where both AstraZeneca and GlaxoSmithKline have research connections.
The question of which country is the best one to invest in – China or India – is being hotly debated in the pharmaceutical sector.
Source:
AZ to invest $100m in Chinese Research
Financial Times, May 27/May 28 2006
Review by Morice Mendoza
This article was first published on World Business
Related articles
Additional Information
Latest jobs Jobs web feed
- Head of Digital Vax Competitive + Excellent Benefits, Central Birmingham
- Group Brand Manager: Lucozade Sport GSK Competitive salary and benefits, Brentford
- Senior Account Director / Group Account Director [Experiential & Integrated] up to £60k - London Fill Recruitment Ltd Up to £60k, Central London
- business director > BIG NAME AGENCY collectivo Up to £90k + bens, London
- Project Director - Leading Digital and Direct Agency - Automotive - £55-65K Fill Recruitment Ltd £55-65K, Clerkenwell
- Senior Social Strategist / Planner The Social Partners £70,000 + Annual bonus, London
Most read
Most commented
